Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Remsima Stars In Orion Pharma’s First Half

Executive Summary

Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.

You may also be interested in...



J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears

The pharma is confident in its current discounting to protect Remicade market share in the US – it still plans to focus on a strategy involving bundling and relying on brand loyalty.

J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears

The pharma is confident in its current discounting to protect Remicade market share in the US – it still plans to focus on a strategy involving bundling and relying on brand loyalty.

Biosimilars A Driving Force Behind Korean Pharma Exports

Remsima/Inflectra's rapid penetration into global biosimilar markets is helping Celltrion to grow into a global biologics powerhouse and also boosting South Korea's pharma exports. The country has logged a biologics trade surplus for the first time in years, due mainly to a surge in exports of biosimilar infliximab, and trend only set to continue with more approvals and launches on the horizon.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM009163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel